Traws Pharma, Inc. (TRAW)Healthcare | Biotechnology | Newtown, United States | NasdaqCM
1.25 USD
+0.04
(3.306%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.24 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:43 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:51 p.m. EDT
Catastrophic near-term tailwinds evaporate following the FDA clinical hold on tivoxavir marboxil, evidenced by the relentless price tumble from 1.75 to 1.25 over the last two weeks. While analyst consensus remains 'strong buy' with a $5.50 target, the deterioration in fundamentals (-100% revenue growth) and the critical cash burn threshold combined with zero insider buying suggest a high-risk downside scenario. The company is currently capitulating in the short term while remaining a cash-constrained, speculative long-term hold. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.306097 |
| AutoETS | 0.318681 |
| AutoARIMA | 0.318718 |
| MSTL | 0.320264 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 59% |
| H-stat | 2.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.336 |
| Excess Kurtosis | -0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.339 |
| Market Cap | 12,696,571 |
| Trailing P/E | 1.52 |
| Forward P/E | -0.40 |
| Profit Margins | 328.67% |
| Previous Name | Onconova Therapeutics, Inc. |
| Website | https://www.trawspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28977275 |
| Address1 | 12 Penns Trail |
| All Time High | 1,751,062.5 |
| All Time Low | 0.97 |
| Ask | 1.27 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 324,410 |
| Average Daily Volume3 Month | 172,222 |
| Average Volume | 172,222 |
| Average Volume10Days | 324,410 |
| Bid | 1.22 |
| Bid Size | 1 |
| Book Value | 0.637 |
| City | Newtown |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.25 |
| Current Ratio | 0.716 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.25 |
| Day Low | 1.08 |
| Display Name | Traws Pharma |
| Earnings Call Timestamp End | 1,723,723,200 |
| Earnings Call Timestamp Start | 1,723,723,200 |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -17,852,332 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.497 |
| Enterprise To Revenue | 3.182 |
| Enterprise Value | 8,876,571 |
| Eps Current Year | -2.93 |
| Eps Forward | -3.09 |
| Eps Trailing Twelve Months | 0.82 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 267 759 3681 |
| Fifty Day Average | 1.7616 |
| Fifty Day Average Change | -0.5116 |
| Fifty Day Average Change Percent | -0.29041782 |
| Fifty Two Week Change Percent | -28.977276 |
| Fifty Two Week High | 3.27 |
| Fifty Two Week High Change | -2.02 |
| Fifty Two Week High Change Percent | -0.617737 |
| Fifty Two Week Low | 0.97 |
| Fifty Two Week Low Change | 0.27999997 |
| Fifty Two Week Low Change Percent | 0.28865975 |
| Fifty Two Week Range | 0.97 - 3.27 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,374,759,000,000 |
| Float Shares | 4,825,002 |
| Forward Eps | -3.09 |
| Forward P E | -0.40453076 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 2,790,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15604 |
| Held Percent Institutions | 0.33657002 |
| Implied Shares Outstanding | 10,157,257 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,727,049,600 |
| Last Split Factor | 1:25 |
| Long Business Summary | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. |
| Long Name | Traws Pharma, Inc. |
| Market | us_market |
| Market Cap | 12,696,571 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_865203 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | 9,170,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,696,571 |
| Number Of Analyst Opinions | 2 |
| Open | 1.22 |
| Operating Margins | -6.4068103 |
| Payout Ratio | 0.0 |
| Phone | 267 759 3680 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.79999924 |
| Post Market Price | 1.24 |
| Post Market Time | 1,776,469,407 |
| Prev Name | Onconova Therapeutics, Inc. |
| Previous Close | 1.21 |
| Price Eps Current Year | -0.42662114 |
| Price Hint | 4 |
| Price To Book | 1.9623233 |
| Price To Sales Trailing12 Months | 4.550742 |
| Profit Margins | 3.28674 |
| Quick Ratio | 0.683 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 3.30578 |
| Regular Market Day High | 1.25 |
| Regular Market Day Low | 1.08 |
| Regular Market Day Range | 1.08 - 1.25 |
| Regular Market Open | 1.22 |
| Regular Market Previous Close | 1.21 |
| Regular Market Price | 1.25 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 376,854 |
| Return On Assets | -0.628 |
| Revenue Growth | -1.0 |
| Revenue Per Share | 0.339 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 10,157,257 |
| Shares Percent Shares Out | 0.0454 |
| Shares Short | 411,637 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 519,827 |
| Short Name | Traws Pharma, Inc. |
| Short Percent Of Float | 0.0743 |
| Short Ratio | 5.58 |
| Source Interval | 15 |
| State | PA |
| Symbol | TRAW |
| Target High Price | 8.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 5.5 |
| Target Median Price | 5.5 |
| Total Cash | 3,820,000 |
| Total Cash Per Share | 0.376 |
| Total Debt | 0 |
| Total Revenue | 2,790,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.82 |
| Trailing P E | 1.5243902 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.8893 |
| Two Hundred Day Average Change | -0.6393 |
| Two Hundred Day Average Change Percent | -0.3383793 |
| Type Disp | Equity |
| Volume | 376,854 |
| Website | https://www.trawspharma.com |
| Zip | 18,940 |